Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer

Abstract

To cite this version:Daphne Hompes, Theo Ruers. Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. EJSO -European Journal of Surgical Oncology, WB Saunders, 2011, 37 (9) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. period of minimally 28 days should be respected before starting BV. Conclusion:Reported rates of BV-related SAE in relationship to surgery are low.

Unusual Bevacizumab-Related Complication of an Oral Infection

“…It is advised that bevacizumab should be stopped at least 5 to 8 weeks before a surgical intervention and restarted 4 weeks later or until the wound is fully healed, with a risk of uncontrolled tumor evolution and/or recurrence. 14 For wound-healing complications, bevacizumab treatment needs to be interrupted until complete healing (28 to 42 days). 14 Although the bone in the oral cavity was exposed in the present patient, necrosis seemed to be localized only to the soft tissues.…”

“…14 For wound-healing complications, bevacizumab treatment needs to be interrupted until complete healing (28 to 42 days). 14 Although the bone in the oral cavity was exposed in the present patient, necrosis seemed to be localized only to the soft tissues. No teeth mobility appeared during surveillance, and progressive reattachment of the soft tissue to the bone occurred after daily soft tissue curettage.…”

Bowel Perforation Following Continuation of Bevacizumab Post Nasal Septal Perforation―A Case Report

“…The risk is higher for patients with colorectal cancer, and could be related to dose, comparing 5 mg/kg/week (RR 6.95 (95% CI 0.36-133.97)) with 2.5 mg/kg/week (RR 2.86 (95% CI 1.11-7.35)) [6]. A subsequent literature review by Hompes (2011) [7] recounts that from the First BEAT study, patients with unresected primary tumours treated with bevacizumab and GI perforation was seen in 8 of 223 (4%): only 3 of which occurring at the primary tumour site [8]. In the BRiTE study, GI perforation rate for this group of patients was 3%, versus almost 2% in patients that the primary tumour had been resected [9].…”

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

“…Post-operative wound healing complications observed in both animal studies and patients who underwent major surgery during bevacizumab treatment had been observed [11,12]. Based on this finding, surgery is recommended to be performed more than 28 days after the last administered dose of bevacizumab whenever possible [13,14]. In BRiTE, serious (grade 3/4) post-operative wound healing complications occurred in 4% of patients undergoing any type of surgery after starting bevacizumab.…”